Comparative Pharmacology
Head-to-head clinical analysis: SULFAIR 10 versus SULFAIR FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAIR 10 versus SULFAIR FORTE.
SULFAIR 10 vs SULFAIR FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Folate antagonist; inhibits dihydropteroate synthetase in bacterial folate synthesis pathway.
5 mg orally once daily, taken at bedtime.
1-2 tablets (sulfamethoxazole 400 mg/trimethoprim 80 mg per tablet) orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life of 8-12 hours in adults with normal renal function (CrCl >60 mL/min); extends to 20-30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment (up to 20-30 hours), necessitating dose adjustment.
Renal excretion of unchanged drug (approximately 70-80%) and hepatic metabolism (20-30% as metabolites). Fecal elimination is minimal (<5%).
Primarily renal excretion of unchanged drug (approx. 70-80%) and glucuronide conjugates; biliary excretion accounts for less than 20%; fecal elimination minimal.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)